Log in to MyACC
SGLT2 Inhibitors and CV and Renal Outcomes in Type 2 Diabetes
Study Questions:
What is the magnitude of the efficacy and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular (CV) and renal outcomes and in relevant subgroups?
Methods:
The investigators did a systematic review and meta-analysis of randomized, placebo-controlled, CV outcome trials of SGLT2i in patients with type 2 diabetes. They searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardized data form and any discrepancies were resolved by consensus. Efficacy outcomes included major adverse cardiac events (MACE; myocardial infarction, stroke, or CV death), the composite of CV death or hospitalization for heart failure (HF), and progression of renal disease. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled across trials, and efficacy outcomes were stratified by baseline presence of atherosclerotic CV disease (ASCVD), HF, and degree of renal function.
Results:
Authors included data from three identified trials and 34,322 patients (60.2% with established ASCVD), with 3,342 MACE, 2,028 CV deaths, or hospitalizations for HF events, and 766 renal composite outcomes. SGLT2i reduced MACE by 11% (HR, 0.89; 95% CI, 0.83–0.96; p = 0.0014), with benefit only seen in patients with ASCVD (HR, 0.86; 95% CI, 0.80–0.93) and not in those without (HR, 1.00; 95% CI, 0.87–1.16; p for interaction = 0.0501). SGLT2i reduced the risk of CV death or hospitalization for HF by 23% (HR, 0.77; 95% CI, 0.71–0.84; p < 0.0001), with a similar benefit in patients with and without ASCVD and with and without a history of HF. SGLT2i reduced the risk of progression of renal disease by 45% HR, 0.55; 95% CI, 0.48–0.64; p < 0.0001), with a similar benefit in those with and without ASCVD. The magnitude of benefit of SGLT2i varied with baseline renal function, with greater reductions in hospitalizations for HF (p for interaction = 0.0073) and lesser reductions in progression of renal disease (p for interaction = 0.0258) in patients with more severe kidney disease at baseline.
Conclusions:
The authors concluded that SGLT2i have robust benefits on reducing hospitalization for HF and progression of renal disease regardless of existing ASCVD or a history of HF.
Perspective:
This meta-analysis of SGLT2i CV outcome trials reports that SGLT2i have their greatest and most consistent effect on reducing risk of hospitalization for HF and of progression of renal disease, and was observed regardless of the presence of established ASCVD or a history of HF. However, the reduction in MACE was apparent only in patients with established ASCVD, whereas no effect was observed in patients without ASCVD. Based on the totality of the evidence, it appears reasonable to consider SGLT2i in patients with type 2 diabetes regardless of ASCVD or history of HF, since they safely reduce hemoglobin A1c and reduce the risk of hospitalization for HF and progression of renal disease across the spectrum of patients with diabetes.
Keywords: AHA Annual Scientific Sessions, AHA18, Atherosclerosis, Diabetes Mellitus, Type 2, Glycated Hemoglobin A, Heart Failure, Kidney Diseases, Metabolic Syndrome, Myocardial Infarction, Outcome Assessment, Health Care, Primary Prevention, Renal Insufficiency, Secondary Prevention, Sodium-Glucose Transport Proteins, Stroke, Vascular Diseases
< Back to Listings
